9R5.F Spermosens AB (publ)
- Market cap
- EUR 1.27M
- P/E
- -
- P/B
- 0.51x
- ROE
- -36.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9R5.F undervalued?
Graham numberThe Graham number of Spermosens AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spermosens AB (publ) fundamental analysis
No fundamental analysis for Spermosens AB (publ) yet.
Spermosens AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorporated in 2018 and is headquartered in Lund, Sweden.
Full company profileSpermosens AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spermosens AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 38.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.63M | 724K | - | - | - | - |
| Operating Income | -6.15M | -19.1M | -10.9M | -9.16M | -9.20M | -9.92M |
| EBITDA | - | -19.0M | -10.7M | -8.98M | -9.02M | -9.74M |
| Net Income | -6.42M | -19.2M | -12.2M | -10.2M | -9.20M | -9.92M |
| EPS | -0.08 | -0.20 | -0.06 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | 25.7M | 9.66M | 26.1M | 31.0M | 33.9M | 28.9M |
| Total Liabilities | 2.04M | 3.84M | 13.4M | 3.70M | 1.53M | 1.47M |
| Shareholders' Equity | 23.6M | 5.83M | 12.7M | 27.3M | 32.4M | 27.5M |
| Cash & Short-term Investments | 6.69M | 552K | 4.49M | 659K | 6.84M | 1.88M |
| Cash Flow | ||||||
| Operating Cash Flow | -5.57M | -18.3M | -10.9M | -7.76M | -10.8M | -9.60M |
| Capital Expenditure | 13.1M | 7.26M | 12.3M | 4.60M | 1.53M | 316K |
| Free Cash Flow | -18.7M | -25.5M | -23.2M | -12.4M | -12.4M | -9.92M |
| Ratios | ||||||
| ROE | -27.2% | -329.3% | -96.1% | -37.3% | -28.4% | -36.1% |
| ROA | -25.0% | -198.6% | -46.7% | -32.9% | -27.1% | -34.3% |
| Net Profit Margin | -16,902.6% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Spermosens AB (publ) dividends
Spermosens AB (publ) has not paid dividends in the last 5 fiscal years.
Who owns Spermosens AB (publ)
- Insiders 20.48%
- Institutions 10.27%
- Public & others 69.25%
- Shares outstanding 3.17B
- Free float 2.45B
Spermosens AB (publ) company profile
- Company name
- Spermosens AB (publ)
- Ticker
- 9R5.F
- ISIN
- SE0015346424
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 4
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 81
- Website
- spermosens.com
About Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorporated in 2018 and is headquartered in Lund, Sweden.
Spermosens AB (publ) management
4- Dr. Tore DuvoldChief Executive Officer · born 1968
- Mr. Alexander DahlquistPart Time Chief Financial Officer · born 1971
- Dr. Jaime Castillo-LeonChief Technology Officer
- Dr. Maria LiljanderChief Scientific Officer